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Friend murine leukemia virus (Fr-MLV) clone A8 causes thymoma 7 weeks postinfection in rats with a more rapid progression than clone
57. The U3 region of A8-LTR contains a unique structure of enhancer motifs consisting of three repeats of a 38-bp sequence containing FVa,
LVb/C4, and CORE motifs. Replacement or deletion of the 38-bp sequence in the A8-U3 resulted in a marked reduction in tumorigenicity.
Furthermore, the virus with 57-U3 gained high tumorigenicity after construction of the three 38-bp repeats in the U3 region. These findings
indicated that the repeats of the 38-bp sequence of A8-LTR are essential for the rapid induction of thymoma. Interestingly, the repeat of the
38-bp sequence did not accelerate the amount of integrated viral DNA in the thymus during the early phase of infection, although it
contributed to higher production of infectious virus. Thus, it was demonstrated that the ability to induce thymoma, which correlates with virus
titer in the thymus, is not determined by the rate of viral DNA integration into the host genome.
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Friend murine leukemia virus (Fr-MLV) clone A8 is a
replication-competent virus and has been isolated as a
neuropathogenic variant that causes spongiform neurode-
generation when inoculated into newborn rats (Takase-
Yoden and Watanabe, 1997; Watanabe and Takase-Yoden,
1995). The replication-competent Fr-MLVs, including A8,
induce erythroleukemia in mice, although the viruses carry
no oncogenes. On the contrary, the tumorigenicity of most
Fr-MLVs against rats is low or absent (Czub et al., 1995;
Masuda et al., 1992; Takase-Yoden and Watanabe, 1997).
However, A8 virus has high tumorigenic potential against
both rats and mice (Takase-Yoden and Watanabe, 1999).
When the A8 virus was inoculated into newborn rats,
thymoma and infiltration of leukemic cells to the organs
were induced 7–8 weeks postinfection, while Fr-MLV
clone 57 induced lymphoma 20 weeks or more postinfec-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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ClaI–KpnI fragment of A8, which contains a 0.1-kb 3V
p15E region, 0.04-kb uncoding region, LTR-U3, and
0.04-kb 5V R region, is crucial for the induction of rapidly
progressive thymoma (Takase-Yoden and Watanabe,
2002). For retroviruses lacking v-onc genes, including
replication-competent Fr-MLV, proviral integration adja-
cent to proto-oncogenes of host cells, a phenomenon
termed proviral insertional mutagenesis, plays a central
role in tumor induction (Rosenberg and Jolicoeur, 1997).
For the induction of rapid tumorigenesis by retroviral
infection, two mechanisms are assumed to be involved.
Firstly, the ability of the enhancer elements in the viral
LTR to activate proto-oncogene is high. Secondly, there is
an abundance of provirus. This increases the chance of
insertional mutagenesis and accelerates tumorigenicity.
The contribution of the transcriptional strength of enhancer
elements to tumorigenicity has been studied (Bosze et al.,
1986; Broussard et al., 2002; Celander and Haseltine,
1984; Dai et al., 1998; Short et al., 1987). However, the
relationship between the amount of integrated viral DNA
in the target tissue and the ability to induce tumors is not
clear.
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have been identified and termed FVa, FVb1, FVb2, and FVc
in addition to NF1 (Manley et al., 1989). The U3 region of
A8 virus, unlike the U3 regions of other Fr-MLVs including
57 virus, contains a unique structure of enhancer motifs
consisting of three tandem direct repeats of a 38-bp fragment
(38Fr) containing the FVa motif. Namely, in the LTR-U3 of
A8 virus, a sequence of five nuclear factor-binding regions,
38Fr, 38Fr, 38Fr, FVb2/NF1, and FVc, was identified
(Takase-Yoden and Watanabe, 2002), while in the LTR-U3
of 57, which is a prototype of Fr-MLV, the second nuclear
factor-binding site is an FVb2/NF1 instead of the 38Fr, and
an additional FVb1 was found in the fourth nuclear factor-
binding site of the FVb2/NF1. The 38-bp fragment in A8-
LTR also contains LVb, C4, and CORE motifs in addition to
FVa. The LVb site, which was identified in the LTR of
Moloney MLV (Mo-MLV) (Speck and Baltimore, 1987) and
is also-called the ETS site, can bind to multiple members of
the ETS family of transcriptional factors (Golemis et al.,
1990; Manley et al., 1993; Speck and Baltimore, 1987; Sun
et al., 1995). The C4 motif has been identified to bind to
GATA-1. GATA-1 is a positive regulator of globin gene
transcription and a member of the GATA family of DNA
binding proteins (Barat and Rassart, 1998). GATA-1,
GATA-2, and GATA-3 are involved in the regulation of
the hematopoiesis-specific genes (Orkin, 1992) and are
required for normal hematopoietic development in mice
(Orkin, 1995; Tsai et al., 1994; Weiss and Orkin, 1995).
The protein that binds to CORE sites of Mo-MLVand SL3-3
MLV has been identified as core-binding factor (CBF) and
purified (Kamachi et al., 1990; Losardo et al., 1990; Speck
and Baltimore, 1987; Thornell et al., 1988; Wang and Speck,
1992). Numerous studies have emphasized the importance
of CBF in hematopoiesis (Niki et al., 1997; O’donnell et al.,
1984; Sasaki et al., 1996; Wang et al., 1996).
In this study, we tested the effect of the enhancer motifs
of Fr-MLV on tumorigenicity in rats. We constructed
enhancer mutant viruses on a background of both high-
and low-tumorigenic viruses, and inoculated them into
newborn rats. The results indicate that the 38-bp sequence
containing FVa, LVb/C4, and CORE motifs is crucial for
the induction of rapidly progressive thymoma in rats.
Furthermore, we tested the production of enhancer mutant
viruses in target tissues, the amount of proviral DNA in the
thymus, and the transcriptional activities of LTRs, and
discussed their contributions to the potential of Fr-MLV
to induce thymoma.Fig. 1. Structures of the enhancer-mutant viruses. The 38-bp fragment
(38Fr) contains the enhancer motifs FVa, LVb, C4, and CORE. FVa, FVb1,
FVb2, FVc, and NF1 represent nuclear factor binding sites identified in
LTR-U3 of Fr-MLV. The LTR-U3 of A8 has an HphI site, but that of 57
does not. The LTR-U3 of 57 has a BsiEI site instead of the HphI site. In
recombinant viral genomes, solid regions are sequences derived from A8
virus and open regions are sequences derived from 57 virus.Results
Construction of the enhancer mutant viruses and the
tumorigenicity in rats
To test the effects of enhancer elements on the tumori-
genicity of MLV in rats, we constructed enhancer mutantviruses based on the high-tumorigenic virus R7a carrying
A8-LTR (Fig. 1A) and low-tumorigenic Rec5 carrying 57-
LTR (Fig. 1B), and inoculated them into newborn rats. R7c
consists of two 38-bp fragments, two FVb2/NF1, and an
FVc motif on the background of R7a. R7d lost two repeats
of the 38-bp sequence from R7a. R5a consists of three 38-bp
S. Takase-Yoden, R. Watanabe / Virology 326 (2004) 29–40 31fragments, an FVb2/NF1, an FVb1, and an FVc motif on the
background of Rec5. The nucleotide sequences in the
enhancer regions of these mutants are shown in Fig. 2.
When rats were inoculated with 6.4  104 XC-PFU of
R7a virus, there was extensive enlargement of the thymus
occupying more than half the area of the chest cavity in 8 of
10 rats 7.0–9.9 weeks postinfection, and histologically, the
tumor cells filled the whole area of the thymus accompa-
nied by necrosis and hemorrhage (grade 2) (Table 1). In 2
of 10 rats, enlargement of the thymus was moderate,
accompanied by disruption of the thymic structure due to
the expansion of tumor cell growth (grade 1). Infiltration of
leukemic cells in R7a-infected rats was observed in 8 of 10
rats. When the rats were inoculated with 8.4  104 or 1.0 
104 XC-PFU of R7c virus, thymoma was not induced at all
7.3–8.6 weeks postinfection (Table 1). Infiltration of leu-
kemic cells in R7c-infected rats was observed in 6 of 12
rats. Rats infected with 1.0  104 XC-PFU of Rec5 did not
manifest thymoma or leukemic infiltration 6.7–7.3 weeks
postinfection (Table 1). When the rats were infected with
1.5  104 or 1.1  104 XC-PFU of R5a, grade 2 thymoma
was observed in 3 of 13 rats 6.9–9.4 weeks postinfection,
and 6 of 13 rats exhibited grade 1 thymoma (Table 1).
Leukemic cell infiltration of organs other than the thymus
was observed in R7c- and R5a-infected rats, but no rats
manifested strong infiltration. When the rats were infected
with 1.1  103 XC-PFU of R7d virus, neither thymoma norFig. 2. Alignment of the enhancer region in LTR-U3 of enhancer-mutant viruses.
D88386) and 57 (accession no. X02794), respectively. Binding sites for nuclear fac
GATA, and CBP are identified as the proteins that bind to the LVb, C4, and CORE
dots represent the sequence identity and difference, respectively.leukemic cell infiltration was induced within 21 weeks
postinfection (Table 1). The rats inoculated with R7a virus
at the same dose as R7d exhibited thymoma 7.7–9.0 weeks
postinfection.
To determine whether the difference in tumorigenicity
among enhancer mutant viruses was significant, the degree
of thymoma and leukemic cell infiltration of organs other
than the thymus 6.7–7.9 weeks postinfection was scored.
When compared with R7a and R7c, the difference in degree
of thymoma was significant (P < 0.001) (Table 2). R5a
induced thymoma to a higher degree compared with Rec5
(P < 0.01), but to a lower degree compared with R7a (P <
0.01). There was no significant difference between the
degree of leukemic cell infiltration caused by R7a-infection
and that caused by R7c-infection (Table 2). R5a induced
leukemic cell infiltration, but the degree was not signifi-
cantly higher compared with Rec5.
Production of the enhancer mutant viruses in rat organs
We investigated the level of production of mutant viruses
in animals. At 2.9 weeks postinfection, virus recovery from
the thymus of rats infected with R7a was 1 order of
magnitude higher compared with R7c-infected rats (Table
3). When Rec5 was infected into rats, virus recovery from
the thymus was not detected 2.9 weeks postinfection in this
assay. Virus recovery from the thymus of R5a-infected ratsThe sequences of R7a-LTR and Rec5-LTR are identical A8 (accession no.
tors; FVa, LVb, C4, CORE, FVb1, FVb2, FVc, and NF1 are indicated. ETS,
motifs, respectively. The XhoI-linker sequence is underlined. Asterisks and
Table 1
Tumorigenicity of enhancer mutant viruses in rats
Infected with Inoculum
(XC-PFU/rat)
Weeks
postinfection
Thymomaa Infiltration
of organs other
than the thymusa
R7a 6.4  104 7.0 ++ +
7.1 ++ +++
7.1 ++ +
7.1 + 
7.4 + 
7.6 ++ +++
8.1 ++ +
8.9 ++ +++
9.9 ++ ++
9.9 ++ ++
1.1  103 7.7 ++ +++
7.7 + 
7.7  
7.7  
7.7  
9.0 ++ 
9.0 + 
9.0 f+ 
9.0 +f++ 
R7c 8.4  104 7.3  +
7.3  
7.3  +
7.6  +
7.6  
7.6  +
7.6  
7.9  +
7.9  +
7.9  
1.0  104 8.6  
8.6  
Rec5 1.0  104 6.7  
6.7  
6.7  
6.7  
6.7  
7.1  
7.1  
7.1  
7.1  
7.3  
7.3  
7.3  
7.3  
R5a 1.5  104 6.9 + +
6.9 + +
6.9  
6.9 + 
7.4 + 
7.4 + 
7.4  
7.4 ++ +
7.7 + +
7.7  
7.7  
1.1  104 9.4 ++ NT
9.4 ++ NT
R7d 1.1  103 7.7  
7.7  
7.7  
7.7  
Table 1 (continued )
Infected with Inoculum
(XC-PFU/rat)
Weeks
postinfection
Thymomaa Infiltration
of organs other
than the thymusa
R7d 1.1  103 7.7  
21.0  
21.0  
21.0  
21.0  
21.0  
a The degree of thymoma and leukemic cell infiltration was scored as
described in Materials and methods.
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postinfection. At 6.7–7.9 weeks postinfection, virus recov-
ery from the thymus of R7a-infected rats was 2 orders of
magnitude higher than that of rats infected with R7c. Virus
recovery from the thymus of Rec5- and R5a-infected rats
6.7–7.9 weeks postinfection showed the same level as R7c.
In the spleen, R7a, R7c, Rec5, and R5a were recovered at
similar titers 6.7–7.9 weeks postinfection (Table 3). When
R7d was infected into rats at the titer of 1.1  103 XC-PFU/
rat, virus recovery from the thymus was 4 orders of
magnitude lower than that of rats infected with 1.1  103
XC-PFU of R7a 7.7 weeks postinfection (Table 3). In the
spleen, virus recovery from R7d-infected rats was 1 order of
magnitude lower than that from R7a-infected rats 7.7 weeks
postinfection. Twenty-one weeks postinfection, the virus
was not detected from the thymus in two of three R7d-
infected rats, but in the spleen, the virus was recovered at
similar titers to those 7.7 weeks postinfection (Table 3).
Lower growth of R7d compared with other enhancer mutant
viruses was also observed in cultured cells (data not shown).
Relative amount of integrated viral DNA of enhancer
mutants in the thymus
The amount of integrated viral DNA in the thymus of rats
infected with enhancer mutant viruses was investigated byTable 2
Degree of thymoma and leukemic cell infiltration induced by enhancer
mutant viruses in rats
The numerals enclosed in parentheses represent numbers of rats.
a The degree of thymoma and leukemic cell infiltration was scored as
described in Materials and methods.
* Difference was significant according to the t test (P < 0.01).
** Difference was significant according to the t test (P < 0.001).
y Difference was not significant according to the t test.
Table 3
Viral titers in the thymus and spleen of rats infected with enhancer mutant viruses
Viruses Inoculum Weeks Virus recovery from (XC-PFU/g)
(XC-PFU/rat) postinfection
Thymus Spleen
R7a 6.4  104 2.9 4.0 F 0.8  105 (3) NT
6.7–7.9 2.3 F 1.5  107 (4) 7.0 F 3.2  105 (4)
R7c 8.4  104 2.9 5.3 F 1.6  104 (3) NT
6.7–7.9 1.1 F 0.4  105 (6) 3.4 F 1.6  105 (4)
Rec5 1.0  104 3.0 <a NT
6.7–7.9 2.1 F 0.6  104 (5) 1.4 F 0.7  105 (5)
R5a 1.5  104 2.9 3.3 F 0.6  105 (3) NT
6.7–7.9 6.9 F 5.8  104 (5) 6.4 F 2.8  104 (5)
R7a 1.1  103 7.7 2.9 F 1.6  106 (3) 7.7 F 3.8  105 (3)
R7d 1.1  103 7.7 2.0 F 1.1  102 (5) 2.0 F 1.1  104 (3)
21.0 3.8  103 (3)b 9.7 F 3.8  103 (3)
The numerals enclosed in parentheses represent numbers of rats.
a Less than 2  102 XC-PFU/g.
b Two of three infected rats: less than 2  102 XC-PFU/g.
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shown in Fig. 3B. As a standard for comparison of the
amount of integrated viral DNA among genomic DNA of
the thymus of rats infected with the enhancer mutants,
genomic DNA derived from cultured rat glial cells (F10)
infected with A8 virus was used. The kinetics of the amount
of integrated viral DNA in the thymus of infected rats were
examined. Genomic DNAs were obtained from the thymus
of rats infected with R7a, R7c, Rec5, and R5a 3, 5, and 7
weeks postinfection and subjected to the Alu-LTR PCR. The
relative amount of integrated viral DNA in the thymus
against the amount of integrated viral DNA in A8-infected
F10 cells is presented in Fig. 4. When R7a- and R7c-
infected rats were compared, the amount of integrated viral
DNA in the thymus was comparable 3 and 5 weeks
postinfection. Seven weeks postinfection, the amount of
integrated viral DNA in the thymus of two of three R7a-
infected rats was larger than that of R7c-infected rats. The
amount of integrated viral DNA in the thymus of R5a-
infected rats was larger than that of Rec5-infected rats 3
weeks postinfection, but the amount of integrated viral DNA
in the thymus of Rec5- and R5a-infected rats was compa-
rable 5 and 7 weeks postinfection.
Viral-antigen expression in thymic cells derived from rats
infected with enhancer mutants
The expression of viral antigen in thymic cells derived
from rats infected with R7a and R7c was compared. Two
weeks postinfection, immunoreactivity against Env pro-
tein was not detected in the thymic cells of R7a-infected
rats (Fig. 5A) or R7c-infected rats (data not shown).
Three weeks postinfection, the intensity and frequency of
expression of viral antigens on the thymic cells of R7a-
infected rats were comparable or lower compared to R7c-
infected rats (Figs. 5B and D). In the thymic cells of
R7a-infected rats 7 weeks postinfection, strong immuno-reactivity against Env protein was observed, and most
cells expressed viral antigen (Fig. 5C), while in the
thymic cells of R7c-infected rats 7 weeks postinfection,
the intensity and frequency of expression of viral anti-
gens were low (Fig. 5E).
Luciferase activities measured in transfection of
LTR-luciferase constructs into cultured cells
To determine the transcriptional strength of LTRs of
enhancer mutants, luciferase activities were measured in
the transfection of LTR-luciferase constructs into cultured
cells. In LYM-1 cells derived from the lymph nodes of rats,
the luciferase activity of the R7a-LTR construct was 2-fold
higher than that of the R7c-LTR construct (P < 0.001) (Fig.
6A). The luciferase activities of the R5a- and Rec5-LTR
constructs were comparable. In RS-A cells derived from the
spleens of rats, the luciferase activity of the R5a-LTR
construct was 2-fold higher than that of the Rec5-LTR
construct (P < 0.01) (Fig. 6B), while the luciferase activities
of the R7a- and R7c-LTR constructs were comparable. In
3Y1 cells derived from rat embryos, the luciferase activity of
the R7a-LTR construct was comparable to that of the R7c-
LTR construct, and the luciferase activity of the R5a-LTR
construct also occurred at the same level as the Rec5-LTR
construct (Fig. 6C). When R7c and R5a were compared,
there was no significant difference in luciferase activity in
LYM-1 and RS-A cells. The luciferase activity of the R7d
construct was the lowest among all the cells tested.Discussion
In this report, we tested the effects of the enhancer
regions of LTR-U3 on the tumorigenicity of Fr-MLV in
rats. Our results using the enhancer mutant viruses showed
that the 38-bp sequence containing FVa, LVb/C4, and
Fig. 4. Kinetic analysis of the amount of integrated viral DNA in the
thymus of rats infected with R7a, R7c, R5a, and Rec5. Alu-LTR PCR of
genomic DNA from the thymus of rats infected with R7a, R7c, Rec5, and
R5a 3, 5, and 7 weeks postinfection was carried out as described in the
legend of Fig. 3 and the text. Aliquots of the PCR products were resolved
on an agarose gel and visualized by ethidium bromide staining, and
intensity of the band was measured using an image-analyzer. As a standard
DNA for normalization of the amount of integrated viral DNA of the
thymus in each experiment, the genomic DNA of A8-infected F10 cells was
serially diluted and subjected to the first PCR. An aliquot of the diluted first
PCR product was further subjected to the second round PCR using nested
MLV LTR-specific primers. The intensity of bands of specific PCR
products increased proportionally against the logarithmic value of the
amount of template genomic DNA (data not shown). The plot obtained
using genomic DNA of A8-infected F10 cells was used as the standard
curve for comparison of the amount of integrated viral DNA in the thymus.
The relative amount of integrated viral DNA in the thymus against the
amount of the control DNAwas calculated. Means of values from three rats
and SEM are shown.
Fig. 3. Quantitative analysis of integrated viral DNA in the rat thymus. (A)
Strategy to detect integrated viral DNA using Alu-LTR PCR. First PCR was
performed using 5Vprimers from the conserved rat Alu-like sequence and 3V
primer from the conserved MLV LTR sequence. Both cellular DNA
upstream of the viral integration site and integrated MLV LTR were
amplified. An aliquot of the product of the first PCR was further subjected
to a second PCR using nested MLV LTR-specific primers. (B)
Representative results of Alu-LTR PCR of genomic DNA from the thymus
of rats infected with R7a 5 weeks postinfection (1st PCR+). Genomic DNA
from the thymus was serially diluted starting with 100 ng of DNA. The
products of two rounds of PCR were resolved in an agarose gel and
visualized under an image-analyzer after ethidium bromide staining.
Genomic DNA from F10 cells infected with A8 virus was used as a
standard for normalization of the amount of integrated viral DNA of the
thymus in each experiment. As controls, first PCR was performed without
DNA polymerase, and then, an aliquot of the mixture was subjected to a
normal second-round of nested PCR (1st PCR). The second round of PCR
using nested MLV LTR-specific primers in this method did not directly
amplify the viral DNA of A8-infected F10 cells and the thymus of rats
infected with R7a.
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progressive thymoma in rats (Fig. 2). The functions of
FVa in the pathogenicity of the virus and a protein bound
to FVa were not identified. However, the LVb site, which
binds to the ETS family of transcriptional factors, is
important for the leukemogenicity of Mo-MLV. Mutation
of the LVb site of Mo-MLV reduces the lymphomagenic
potential of the virus (Speck et al., 1990). Recently, it was
demonstrated that the LVb site is essential for full activation
of the retrovirus enhancer in T cells (Wahlers et al., 2002).
GATA-1, which is bound to C4 sites, has been shown to
transactivate LTR of Fr-MLV 15-fold in transient transfec-
tion in CV1 cells (Chang et al., 1994). The core-binding
factor (CBF) plays an important role in the leukemo-pathogenic properties of Mo-MLV (Lewis et al., 1999)
and other MLVs (Boral et al., 1989; Speck et al., 1990).
Thus, our finding that the 38-bp fragment of A8-LTR is
important for the induction of thymoma is consistent with
the previous findings on the functions of these enhancer
motifs in thymic cells. The finding that the degree of
thymoma induced by R5a-infection did not reach that by
R7a-infection indicates that the downstream region of the
HphI site in the U3 of A8 (the HphI–AatII fragment, Fig. 1)
containing the 5V leader sequence of A8 partially contributes
to the induction of thymoma (Table 2). However, the rate of
contribution of the HphI–AatII fragment of A8 to the
induction of thymoma is lower compared with the 38-bp
repeat sequence because R7c did not cause thymoma 7
weeks postinfection (Table 2). On the contrary, the HphI–
AatII fragment of A8 is important for the infiltration of
leukemic cells into organs other than the thymus, but the 38-
bp repeat sequence of A8 is not essential for leukemic cell
infiltration (Table 2). The rapid progression of leukemic
infiltration seemed to be regulated by different mechanisms
from the rapid progression of thymoma induced by the A8
viral gene.
Fig. 5. Expression of viral antigen in the rat thymus infected with R7a (A, B, C, and F) or R7c (D and E) 2 (A), 3 (B and D), and 7 weeks (C, E, and F)
postinfection. Suspended thymic cells were spun down directly on the glass slides, fixed with ethanol, followed by application of goat anti-Rauscher murine
leukemia virus gp70 (A–E) or normal goat serum (F) for immunofluorescence. The upper part of each figure is a phase-contrast picture of the same area shown
in the lower part for immunofluorescence. Two weeks postinfection, viral antigen was not detected (A). 30–40% of the thymic cells became viral antigen-
positive 3 weeks postinfection with R7a (B) almost in the same manner as R7c (D). Seven weeks postinfection with R7a, nearly 100% of the thymic cells
expressed viral antigen (C) while the percentage of viral antigen-positive cells was even decreased 7 weeks after the R7c infection (E) compared to the thymus
3 weeks after the infection. Scale bars indicate 30 Am.
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induction of thymoma with rapid progression in rats? To
resolve this question, we first compared viral proliferation in
the thymus and spleen of rats infected with enhancer mutant
viruses 3 and 7–8 weeks postinfection. We especially noted
an early phase of infection before manifestation of thymoma.
Virus titers of R7a and R5a in the thymus 3 weeks postin-
fection were 10-fold or more higher than those of R7c and
Rec5 (Table 3). On the contrary, 7–8 weeks postinfection in
the thymus, the virus titers of R7a were 100-fold higher than
those of R7c, but those of Rec5 and R5a were the same level.In the spleen 7–8 weeks postinfection, the virus titers of R7a,
R7c, Rec5, and R5a were comparable. These findings indi-
cated that the 38-bp fragment contributes to the enhancement
of viral production in the thymus at the early phase of
infection. Furthermore, the viral titers in the thymus 3 weeks
postinfection were well correlated with the tumorigenic
potential of viruses (Table 2).
The findings that viral production at a high level is
important for rapid tumorigenesis coincide with previous
findings. The best-understood process in tumorigenicity
by retroviruses lacking v-onc genes is insertional activa-
Fig. 6. Luciferase activities directed by the LTR of plasmids transfected into LYM-1 cells derived from lymph nodes of rats (A), RS-A cells derived from the
spleens of rats (B), and 3Y1 cells derived from rat embryos (C). The plasmids contain LTR of R7a, R7c, R7d, Rec5, and R5a, firefly luciferase gene, and
polyadenylation signal (D). The LTR-luc plasmids and pRL-SV40 carrying the renilla luciferase gene, as an internal control, were transfected into cells. After 2
days, the luciferase activities were measured using the Dual-Luciferase Reporter Assay System. Means of values from three independent experiments and SEM
are represented. * Denotes difference was not significant according to the t test.
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gene near proto-oncogenes occur by chance as a conse-
quence of the normal viral life cycle, it is assumed that
the accumulation of proviruses in target tissues is impor-
tant for the rapid induction tumors. So, is the amount of
integrated viral DNA in the thymus of rats infected with
highly proliferative virus larger than that of rats infected
with weakly proliferative virus? We measured the amount
of integrated viral DNA in the thymus of rats infected
with enhancer mutant viruses using Alu-LTR PCR meth-
ods. This method specifically detects the presence of
integrated viral DNA sequences as opposed to episomal
viral DNA forms using primers directed to Alu repeat
elements and anti-sense primer to the LTR of A8 MLV.
The rat genome contains Alu-like repeats (Alonso et al.,
1983), and we were able to detect the integrated viral
DNA in the genomic DNA of rat tissues (Fig. 3). When
compared with high-tumorigenic R7a and low-tumorigen-
ic R7c, the amount of integrated viral DNA in the
thymus was the same during the period 3–5 weeks
postinfection (Fig. 4). Immunofluorescence for viral anti-
gen expression shows that the frequency of expression of
viral antigens on the R7a-infected thymus was equivalent
to that in R7c-infected thymus 3 weeks postinfection
(Figs. 5B and D). Thus, integrated viral DNA of high-
tumorigenic virus as well as low-tumorigenic virus is notlocalized in a partial population of thymic cells but is
extensively distributed. Seven weeks postinfection, the
amount of integrated viral DNA in the thymus of two
of three R7a-infected rats was larger than that of R7c-
infected rats. However, this difference could reflect the
expansion of tumor cells that are infected with the virus
and occupy the thymus (Fig. 5C) (Takase-Yoden and
Watanabe, 2002). Furthermore, compared with moderate-
tumorigenic R5a and low-tumorigenic Rec5, the amount
of integrated viral DNA in the thymus was constant over
5–7 weeks postinfection (Fig. 5). These findings indicat-
ed that the three repeats of the 38-bp fragment do not
accelerate the rate of viral DNA integration. It is apparent
that the amount of integrated viral DNA in the thymus is
not related to the tumorigenic potential of viruses. There-
fore, it is suggested that abundant provirus does not lead
to increase in the chances of insertional mutagenesis and
accelerate tumorigenicity.
A discrepancy appears in the relationships among the
amount of integrated viral DNA, virus antigen expression,
and production of infectious viral particles in the thymus
infected with enhancer mutants. The amount of integrated
viral DNA in the thymus in R7a infection was equivalent
to R7c at 3 weeks postinfection (Fig. 4). Similarly, Env
protein expression was equivalent for R7a and R7c at 3
weeks postinfection (Fig. 5). These data are not consis-
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production of R7a virus in the thymus was 10-fold higher
than that of R7c (Table 3). The capability of production
of infectious viruses that brought the discrepancy de-
scribed above may be dependent not on the transcrip-
tional or translational steps, but on the steps afterward,
including the phase of viral maturation, because the
expression levels of Env determined by immunofluores-
cence were similar between R7a and R7c (Figs. 5B and
D), and the amount of subgenomic RNA of R7a, which
codes for Env protein, is possibly equivalent to R7c.
However, the possibility remains that the full-length
genome RNA of R7a could be synthesized in the thymus
in a greater amount, enabling the efficient incorporation
of the viral genome into virions, because R7a-LTR
showed higher transcriptional activity than R7c-LTR
(Fig. 6), as discussed later.
To determine the effects of the 38-bp fragment on the
transcriptional strength of LTR, we measured the luciferase
activities of the LTR-luciferase construct in cultured cells. In
LYM-1 cells, established from rat lymph nodes, the tran-
scriptional activity of R7a-LTR was higher than that of R7c-
LTR (Fig. 6A). In RS-A cells, established from rat spleens,
the transcriptional activity of R5a-LTR was higher than that
of Rec5-LTR (Fig. 6B). In 3Y1 cells, established from rat
embryos, the transcriptional activities of R7a and R7c
showed the same level, and the difference between the
transcriptional activities of R5a- and Rec5-LTR was not
significant (Fig. 6C). These findings indicate that the 38-bp
fragment has the potential to enhance the transcriptional
activity of LTR in hematopoietic tissue-derived cells. How-
ever, the transcriptional activities of Rec5- and R5a-LTRs in
LYM-1 cells occurred at the same level (Fig. 6A), and those
of R7a- and R7c-LTRs in RS-A cells were also the same
(Fig. 6B). Thus, our findings suggested that the BsiEI–AatII
fragment of 57-LTR (Fig. 1B) and the HphI–AatII fragment
of A8-LTR (Fig. 1A) also contribute to the transcriptional
activities of LTR measured in LYM-1 cells and RS-A cells.
The difference between the transcriptional activities of R5a-
and R7c-LTR was not significant in LYM-1 and RS-A cells,
whereas R5a showed tumorigenicity but R7c did not. These
findings indicated that the strength of transcriptional activity
measured using LTR-luciferase constructs partially corre-
lates with the tumorigenicity of the virus. A discrepancy
between the leukemogenic potential of Fr-MLV in mice and
the transcriptional activities of LTR measured using LTR-
reporter gene constructs transfected into cultured cells has
been reported by Dai et al. (1998). The fact that the
transcriptional strength of R7d-LTR was the lowest among
the enhancer mutant viruses in all the cells tested (Figs. 6A,
B, and C) indicates that deletion of the 38-bp fragment
induces a large reduction in enhancer activity. Because the
38-bp fragment is shown to have the potential to enhance
the transcriptional activity of LTR, it is possible that the 38-
bp fragment enhances tumorigenicity by strong activation of
flanking proto-oncogenes.Materials and methods
Viruses and cells
Friend murine leukemia virus (Fr-MLV) clone A8 was
obtained as described previously (Takase-Yoden and Wata-
nabe, 1997). The infectious DNA of Fr-MLV clones 57
(Oliff et al., 1980) and A8 was transfected into NIH3T3
cells, and virus-producing cell cultures were established.
Viral titers were determined by XC cell plaque assay of
C182 cells in the presence of 10 Ag/ml of Polybrene (Rowe
et al., 1970). The cells, except for C182, were grown on
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum (FCS). C182 cells were grown on
minimum essential medium (MEM) supplemented with
10% calf serum.
Construction of enhancer mutant viruses
Enhancer mutant viruses were constructed from high-
tumorigenic R7a and low-tumorigenic Rec5 viruses, which
are chimeric viruses between A8 and 57, as described
previously (Takase-Yoden and Watanabe, 1997, 1999). To
construct R7c, the BlpI–HphI fragment of A8-LTR of R7a
was replaced with the BlpI–BsiEI fragment of 57-LTR. To
connect the HphI and BsiEI sites, XhoI-linker was used. R7d
was constructed from R7a by deletion of 76 bp of the
EcoRV–EcoRV fragment from R7a-LTR. To construct R5a,
the BlpI–BsiEI fragment of 57-LTR of Rec5 was replaced
with the BlpI–HphI fragment of A8-LTR. To connect the
HphI and BsiEI sites, XhoI-linker was used. Structures of
the enhancer mutant viruses were confirmed by digestion
with restriction enzymes and sequence analyses. Basic
recombinant DNA procedures were performed according
to standard methods (Sambrook et al., 1989).
Infection of rats
The ability of viruses to cause disease was assessed using
newborn Lewis rats purchased from a commercial breeder.
Newborn rats were inoculated intraperitoneally with 0.1 ml
and intracerebrally with 0.005 ml of viral supernatant. The
titers of inoculated virus are described in the tables.
After exsanguination of the infected animals, the thymus
and spleen were homogenized in cold phosphate-buffered
saline (PBS) containing 1 mM MgCl2 and 1 mM CaCl2, and
infectious virus titers were determined by the XC cell plaque
assay (Rowe et al., 1970).
Alu-LTR PCR analyses
Genomic DNA was isolated from the thymus and spleen
using QIAGEN Genomic-tips (QIAGEN) according to the
manufacturer’s protocol. To specifically detect integrated
viral DNA but not unintegrated forms, the Alu-LTR PCR
method was utilized (Chun et al., 1997; Courcoul et al.,
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tous repeat elements exist, and the Alu repeat sequence is
the most abundant of these repeat elements (Jelinek and
Schmid, 1982). An Alu-like repeat has also been found in
the rat genome (Alonso et al., 1983; Firulli et al., 1993;
Watson and Sutcliffe, 1987). Primers were designed to
amplify the region between the rat Alu-like sequences and
adjacent LTR sequence. Genomic DNA from the thymus
of rats was serially diluted. The first PCR was carried out
using following primers; rat-Alu-LTR-sense (5V-ATCCAG-
CACTCAGGAGGCAGAGG-3V) from the conserved se-
quence of the rat Alu-like sequence and Alu-LTR-3V-rev
(5V-ACCACAAGTCGGATGCAA-3V) from the conserved
MLV LTR sequence. PCR was performed with a 50-
Al reaction mixture containing 0.2 mM each of deoxyri-
bonucleotides, 0.8 mM MgSO4, 300 nM primers, serially
diluted genomic DNA, and 1 unit of KOD-Plus-DNA
polymerase (TOYOBO, Co., LTD.) in PCR buffer for
KOD-Plus-from the supplier. Mineral oil was overlaid,
and cycling conditions were as follows: denaturation at
94 jC for 2 min, 22 cycles of denaturation at 94 jC for 15
s, annealing at 65 jC for 30 s, and polymerization at 68
jC for 3 min with 10 min at 68 jC for final extension.
Following the initial PCR, a second nested PCR amplifi-
cation was carried out using an aliquot equivalent to 1/400
of the 22-cycle PCR product. The second nested PCR,
which allows amplification of a portion of the LTR of
MLV, was performed using a 50-Al reaction mixture
containing 0.2 mM each of deoxyribonucleotides, 1.2
mM MgSO4, 300 nM primers (A8/57-LTR; 5V-CAGAT-
CAAGGTCAGGTACACG-3V, Alu-LTR-nest-3V-rev; 5V-
CGAGTGAGGGGTTGTGAGCT-3V), serially diluted ge-
nomic DNA, and 1 unit of KOD-Plus-DNA polymerase
(TOYOBO, Co., LTD.) in PCR buffer for KOD-Plus-from
the supplier. Mineral oil was overlaid, and cycling con-
ditions were as follows: denaturation at 94 jC for 2 min,
22 cycles of denaturation at 94 jC for 15 s, annealing at
65 jC for 30 s, and polymerization at 68 jC for 30 s with
10 min at 68 jC for final extension. In control reactions,
genomic DNA that had not been subjected to the round of
PCR was also amplified using the second PCR primers.
Aliquots of the PCR products were analyzed on a 2%
agarose gel and visualized under ImageMaster VDS-CL
(Amersham Pharmacia Biotech) after ethidium bromide
staining. The intensity of the bands was measured using
ImageMaster TotalLab installed in ImageMaster-CL, and
the relative amount of integrated viral DNA against the
amount of integrated viral DNA in control cells, which
were the F10 cells infected with A8 virus, was calculated.
Measurement of transcriptional activities
LTR-luc plasmids were constructed. The ClaI–BalI
fragment containing a 0.1-kb region of the 3V terminus of
the env gene, the intergenic region, LTR, and 0.07 kb of the
5V leader sequence of R7a, R7c, R7d, R5a, and Rec5, thefirefly luciferase gene derived from pSP-luc + NF fusion
vector (Promega), and polyadenylation signal (polyA) were
inserted into multiple cloning sites of pBluescript (SK). As
an internal control, pRL-SV40 vector (Promega) containing
the renilla luciferase gene was used.
LYM-1 cells, provided by Riken Cell Bank (Japan), RS-A
cells, provided by Japanese Collection of Research Biore-
sources (Japan), and 3Y1 cells were used to assay the
transcriptional activities of LTRs. LYM-1 cells were estab-
lished from the lymph nodes of rats (Kurayama et al., 1986)
and grown on DMEM containing 2% FCS. RS-A cells were
established from the spleens of rats (Tokiwa, 1972) and
grown on MEM containing 10% FCS. 3Y1 cells were
established from rat embryos and grown on DMEM con-
taining 10% FCS. LYM-1 (4  105), RS-A (6  105), and
3Y1 (6  105) cells were plated into 6-well plates, and the
next day, transfected with 5 Ag of LTR-luc plasmid and 50 ng
of pRL-SV40 using 10 Al of LipofectAMINE 2000 Reagent
(GibcoBRL) diluted with OPTI-MEM (GibcoBRL). After
2 days, the cells were lysed and luciferase activities were
measured using the Dual-Luciferase Reporter Assay Sys-
tem (Promega) according to the manufacturer’s protocol.
The activity of each sample was normalized by that of
pRL-SV40 used as an internal control.
Histological examinations
After exsanguination of the infected animals, the organs
were immersed in 4% paraformaldehyde buffered with 0.12
M phosphate (pH 7.3) and fixed. The tissues were embed-
ded in paraffin for histological staining with hematoxylin
and eosin. The degree of thymoma was scored as follows:
grade 2, there was extensive enlargement of the thymus
occupying more than half the area of the chest cavity.
Histologically, the tumor cells filled the whole area of the
thymus accompanied by necrosis and hemorrhage; grade 1,
enlargement of thymus was moderate, with disruption of the
thymic structure due to the expansion of tumor cell growth;
grade 0, no thymoma. The degree of leukemic cell infiltra-
tion was scored as follows: grade 3, strong infiltration of
more than three organs; grade 2, strong infiltrations of one
or two organs or mild infiltrations of more than three organs;
grade 1, mild infiltration of one or two organs; grade 0, no
leukemic cell infiltration.
For immunofluorescence, a thymic cell suspension was
prepared after mechanical destruction of the thymus and
passage through stainless steel mesh. After disruption of
red blood cells with 0.017 M Tris–HCl–0.75% NH4Cl, the
suspended thymic cells were washed with cold-PBS three
times and spun down on poly-L-lysin-coated glass slides
using Cytospin III (Shandon, UK). The cells were fixed for
3 min with 100% ethanol and processed for immunofluo-
rescence as described previously (Watanabe and Takase-
Yoden, 1995). Goat anti-Rauscher murine leukemia virus
gp70 (Takase-Yoden and Watanabe, 2001) or normal goat
serum was applied to the fixed cells followed by biotiny-
S. Takase-Yoden, R. Watanabe / Virology 326 (2004) 29–40 39lated rabbit anti-goat IgG (Zymed Laboratories Inc., USA)
and avidin-Alexa Fluor 488 conjugate (Molecular Probes
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